力大圖書

IASLC Thoracic Oncology, 2nd Edition 2018
-胸腔外科
- 編號： 0----0323523579
- 作者： Harvey Pass MD
- 原價-8910 - (熱賣價)7590 - 節省 ↓15%
- 加入購物車提交
推薦指數：
- 內容介紹
IASLC Thoracic Oncology, 2nd Edition
by Harvey Pass MD (Author), David Ball MD FRANZCR (Author), Giorgio Scagliotti MD PhD (Author)
Hardcover: 704 pages
Publisher: Elsevier; 2 edition
Language: English
ISBN-10: 0323523579
ISBN-13: 978-0323523578
Product Dimensions: 1.2 x 8.8 x 11 inches
2018

Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today's best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies.

New to this Edition
Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer.
Features a new full-color design throughout, as well as updated diagnostic algorithms.
Expert Consult™ eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, Q&As, and references from the book on a variety of devices.

Key Features
Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy.
Provides authoritative guidance from the IASLC - the only global organization dedicated to the study of lung cancer.

Author Information
By Harvey Pass, MD, Stephen E. Banner Professor of Thoracic Oncology, Vice Chair of Research NYUHC, Departments of Cardiothoracic Surgery, New York University Langone Medical Center, New York, New York; David Ball, MD, FRANZCR, Director, Lung Cancer Stream, Victorian Comprehensive Cancer Centre, Parkville Professional Fellow, the Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia and Giorgio Scagliotti, MD, PhD, Professor of Medical Oncology, Head of Department of Oncology at S. Luigi Hospital, University of Turin, Orbassano (Torino), Italy

└ 返回上一頁